Publicacións en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (14)

2024

  1. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849

  2. The role of the brain renin-angiotensin system in Parkinson´s disease

    Translational Neurodegeneration, Vol. 13, Núm. 1

2023

  1. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

  2. Extracellular Vesicles and Their Renin–Angiotensin Cargo as a Link between Metabolic Syndrome and Parkinson’s Disease

    Antioxidants, Vol. 12, Núm. 12

2022

  1. Angiotensin System Autoantibodies Correlate With Routine Prognostic Indicators for COVID-19 Severity

    Frontiers in Medicine, Vol. 9

  2. Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease

    npj Parkinson's Disease, Vol. 8, Núm. 1

  3. Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment

    Biomedicines, Vol. 10, Núm. 2

  4. Parkinson's disease and diabetes mellitus: Common mechanisms and treatment repurposing

    Neural Regeneration Research, Vol. 17, Núm. 8, pp. 1652-1658

2021

  1. Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19

    Journal of Autoimmunity, Vol. 122

  2. Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists

    Frontiers in Neuroendocrinology, Vol. 62

  3. Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19

    Clinical Science, Vol. 135, Núm. 3, pp. 465-481

2020

  1. Interaction between brain angiotensin and dopaminergic systems and Parkinson’s disease

    Genetics, Neurology, Behavior, and Diet in Parkinson’s Disease: The Neuroscience of Parkinson’s Disease, Volume 2 (Elsevier), pp. 463-477

  2. Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA

    Frontiers in Neuroanatomy, Vol. 14

  3. Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease

    British Journal of Pharmacology, Vol. 177, Núm. 24, pp. 5622-5641